PharmiNews

The Directory of Pharma Companies and News

Alnylam

Alnylam logo
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam's pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015, Alnylam launched its "Alnylam 2020" guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi therapeutic clinical programs - including 4 in late stages of development - across its 3 STArs. The company's demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and Genzyme, a Sanofi company. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world's top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts.
Category:
Category:

Alnylam News

DateNews
2017-01-03Alnylam Announces Management Change and Key Promotion
2017-01-03Alnylam to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference
2016-12-16Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam 2020 Strategy
2016-12-05Alnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (P...
2016-12-04Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patie...
2016-12-03Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors
2016-12-03Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic ...
2016-11-15The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (for...
2016-11-14Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision for Co-Development and Co-Commercialization of Fitusira...
2016-09-28Alnylam Presents Clinical and Non-Clinical Data Demonstrating Continued RNAi Platform Optimization and Leadership in the...
2016-09-24Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic fo...
2016-09-21Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Operating Officer
2016-09-20Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK
2016-09-19Alnylam Expands and Strengthens Management Team as it Plans for Commercialization
2016-09-07Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AS1, an Investigational RNAi Therapeutic for ...
2016-09-06Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2016-08-08Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients...
2016-08-04Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress
2016-08-02Alnylam to Webcast Presentation at Canaccord Genuity Growth Conference
2016-07-28Alnylam to Webcast Conference Call Discussing Second Quarter 2016 Financial Results
2016-07-25Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia (WFH) 2016 World Congress
2016-07-25Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigationa...
2016-07-12Alnylam to Host Third Annual "RNAi Roundtable" Webcast Series
2016-07-07Alnylam Initiates Phase 1/2 Clinical Trial for ALN-HBV, an Investigational RNAi Therapeutic for the Treatment of Chronic...
2016-07-01Alnylam Reports New Results from Investigational RNAi Therapeutic Programs for Hereditary Transthyretin-Mediated Amyloid...
2016-06-27Alnylam to Report New Patisiran and Revusiran Results at the XV International Symposium on Amyloidosis
2016-06-23Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual "Helping Hands" Community Ser...
2016-06-11Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/...
2016-06-09Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-M...
2016-06-03Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
2016-05-02Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress
2016-04-28Alnylam to Break Ground on New Manufacturing Facility in Norton, Massachusetts
2016-04-25Alnylam to Webcast Conference Call Discussing First Quarter 2016 Financial Results
2016-04-20Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational ...
2016-04-06Alnylam to Webcast Presentation at 15th Annual Needham Healthcare Conference
2016-03-14Alnylam Initiates Fitusiran (ALN-AT3) Dosing in Hemophilia A and B Patients with Inhibitors in Ongoing Phase 1 Study
2016-03-09Alnylam Initiates Phase 1/2 Clinical Trial for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary...
2016-02-29Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2016-02-11Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progres...
2016-02-04Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2015 Financial Results
2016-02-01Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients wi...
2016-02-01Alnylam to Webcast Presentations at Upcoming February Investor Conferences
2016-01-11Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline
2016-01-04Alnylam to Webcast Presentation at 34th Annual J.P. Morgan Healthcare Conference
2015-12-29Alnylam to Webcast Presentation at Goldman Sachs "Healthcare CEOs Unscripted: A View from the Top" Conference
2015-12-21Alnylam Files Clinical Trial Application (CTA) for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Pri...
2015-12-18Alnylam Announces Updates to Company's Board of Directors Supportive of Transition Towards Commercial Stage
2015-12-17Alnylam Initiates Dosing in PNH Patients in Phase 1/2 Clinical Trial for ALN-CC5
2015-12-10Alnylam Pharmaceuticals to Present Path to "Alnylam 2020" at R&D Day
2015-12-07Alnylam Reports Positive Phase 1 Study Results for Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) in Patients with Hemop...
2015-12-06Alnylam Reports that ALN-CC5 Achieves Up to 99 Percent Knockdown of Serum C5 and Up to 98 Percent Inhibition of Serum He...
2015-12-02Alnylam to Webcast R&D Day
2015-11-23Alnylam to Webcast Presentations at Upcoming December Investor Conferences
2015-11-11Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at...
2015-11-09Alnylam Pharmaceuticals Reports Third Quarter 2015 Financial Results and Highlights from Recent Period
2015-11-05Alnylam to Present New Clinical Results with Investigational RNAi Therapeutics at 57th Annual Meeting of the American So...
2015-11-03Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension (OLE) Studies for Patisiran and Revusiran, in...
2015-11-02Alnylam to Webcast Conference Call Discussing Third Quarter 2015 Financial Results
2015-11-02Alnylam to Webcast Presentations at Upcoming November Conferences
2015-10-29Alnylam to Report New Clinical Results with Investigational RNAi Therapeutics for the Treatment of Transthyretin-Mediate...
2015-10-14Alnylam Demonstrates Continued Commitment to Transthyretin-Mediated Amyloidosis Patients with Advancement of ALN-TTRsc02...
2015-10-13Alnylam Advances New Innovations in RNAi Therapeutics
2015-10-08Alnylam Initiates Phase 1 Open Label Extension (OLE) Study with ALN-AT3, an Investigational RNAi Therapeutic for the Tre...
2015-10-01Alnylam and Genzyme Announce that Genzyme Opts into ALN-AT3 Hemophilia Program for Development and Commercialization Out...
2015-09-28Alnylam and Collaborators Report First-Ever Evidence that Patisiran Reduces Pathogenic, Misfolded Transthyretin (TTR) Mo...
2015-09-28Alnylam Granted Summary Judgment by United States District Court for the District of Massachusetts in Tuschl II Patent I...
2015-09-15Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevuli...
2015-09-10Alnylam to Webcast Presentations at Upcoming September Conferences
2015-09-08Alnylam Accelerates Development of ALN-GO1, a Subcutaneously Administered Investigational RNAi Therapeutic for the Treat...
2015-08-30ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for Effective LDL-C Lowering in...
2015-08-06Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities
2015-08-05Alnylam to Webcast Presentation at Canaccord Genuity 35th Annual Growth Conference
2015-07-30Alnylam to Webcast Conference Call Discussing Second Quarter 2015 Financial Results
2015-07-27Alnylam Initiates Phase 1/2 Clinical Trial for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1...
2015-07-20Alnylam Initiates Phase 3 Open Label Extension Study ("APOLLO-OLE") with Patisiran, an Investigational RNAi Therapeutic ...
2015-07-16Alnylam to Reschedule First RNAi Roundtable Webcast
2015-07-06Alnylam to Host Second Annual Summer "RNAi Roundtable" Webcast Series
2015-06-23Alnylam Reports New Positive Clinical Data for ALN-AT3, a Subcutaneously Administered, Investigational RNAi Therapeutic ...
2015-06-12Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement ...
2015-06-10Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals
2015-06-08Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer
2015-06-05Alnylam to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress with ALN-AT3, an...
2015-05-28Alnylam to Webcast Presentations at Upcoming June Investor Conferences
2015-05-26Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid ...
2015-05-20Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for Revusiran, an Investigati...
2015-05-17Alnylam Files Clinical Trial Application (CTA) for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alp...
2015-05-07Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results and Highlights Recent Period Progress
2015-04-30Alnylam to Webcast Conference Call Discussing First Quarter 2015 Financial Results
2015-04-29Alnylam to Webcast Presentations at Upcoming May Investor Conferences
2015-04-21Alnylam Reports 12-Month Clinical Data from Phase 2 Open Label Extension (OLE) Study of Patisiran, an Investigational RN...
2015-04-13Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3, an Investigational RNAi Ther...
2015-04-08Alnylam to Webcast Presentation at 14th Annual Needham Healthcare Conference
2015-03-15Alnylam Presents Results from Natural History Study of Patients with Familial Amyloidotic Cardiomyopathy (FAC) and Prese...
2015-03-13Alnylam to Webcast Presentation at 22nd Annual Future Leaders in the Biotech Industry Conference
2015-03-05Alnylam to Webcast Presentation at Barclays Global Healthcare Conference
2015-02-25Alnylam to Webcast Presentation at Cowen & Company 35th Annual Health Care Conference
2015-02-18Alnylam to Webcast Presentation at 2015 RBC Capital Markets' Global Healthcare Conference
2015-02-12Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Highlights Recent Period Progres...
2015-02-05Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2014 Financial Results
2015-02-03Alnylam to Webcast Presentation at Upcoming Investor Conferences
2015-02-02Alnylam Initiates Phase 1/2 Clinical Trial for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complem...
2015-01-21Alnylam Pharmaceuticals Prices Public Offering of Common Stock
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.